Volvo Cars to cut 3,000 mostly white-collar jobs as part of restructuring
Sweden's Volvo Cars will cut 3,000 mostly white-collar jobs as part of a restructuring announced last month as it grapples with high costs, a slowdown in electric-vehicle demand and trade uncertainty, it said on Monday.
The layoffs represent around 15% of the company's office staff, with close to three-quarters of job losses expected to occur in Sweden and the rest in the company's global operation, Volvo Cars said in a statement.
With most of its production based in Europe and China, Volvo Cars is more exposed to new U.S. tariffs than many of its European rivals, and has said it could become impossible to export its most affordable cars to the United States.
The group, which is majority-owned by China's Geely Holding, on April 29 unveiled a program to slash costs by 18 billion Swedish crowns (US$1.9-billion) and hit the brakes on investments, warning that redundancies were inevitable.
Plummeting EV sales unlikely to rebound anytime soon without incentives, expert says
In the first quarter, the auto maker had 43,500 full-time employees and 3,000 staffing agency personnel, according to its earnings report. White-collar staff make up more than 40 per cent of its work force.
'The automotive industry is in the middle of a challenging period. To address this, we must improve our cash flow generation and structurally lower our costs,' CEO Hakan Samuelsson said.
The group withdrew its financial guidance as it announced its cost cuts last month, pointing to unpredictable markets amid weaker consumer confidence and trade tariffs causing turmoil in the global auto industry.
On Friday U.S. President Donald Trump threatened to impose a 50-per-cent tariff on imports from the European Union from June 1, but on Monday he backed away from that date, restoring a July 9 deadline to allow for talks between Washington and Brussels.
Volvo Cars' shares were up 3.7% at 1145 GMT on Monday to 18.20 crowns, with most of the rise coming before the layoff announcement. They are still down 24% year-to-date.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Novo Nordisk Stock: Is It Still a Smart Buy?
Much like the long-term users of its most popular product, Novo Nordisk 's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. An increasingly crowded field Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Fragmentation and setbacks Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Fighting back Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor 's total average return is789% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
National Post
3 hours ago
- National Post
SES Announces Appointment of New CFO
Article content Elisabeth Pataki, a progressive finance executive with over 20 years of experience at Article content SES's Leadership Team as new CFO Article content LUXEMBOURG — SES today announced its Board of Directors has appointed Elisabeth (Lisa) Pataki as Chief Financial Officer (CFO), effective 16 June 2025. Lisa is a progressive finance executive with over 20 years of experience at various publicly listed multi-national aerospace and defence companies with strong background in company transformation and investment strategies. She will succeed Sandeep Jalan who has been SES's CFO since May 2020. Article content The SES Board acknowledges Sandeep's contribution to SES and wishes him success in future endeavours. Lisa will work closely with Sandeep to ensure a smooth handover before he leaves on 31 July 2025. Article content 'I would like to thank Sandeep for his steadfast leadership over the last five years where he has driven continuous execution improvement and transformation while strengthening the company's balance sheet with a competitive cost of capital and delivering healthy cash returns to shareholders,' said Adel Al-Saleh, CEO of SES. 'We are pleased to welcome Lisa as our new CFO. Lisa has extensive experience in the aerospace and defence ecosystem and has completed several successful M&A finance integrations. Moreover, her ability to develop financial strategies that prioritise operational focus, efficiency, and profitable investments will strengthen SES's Leadership Team, helping SES achieve our mission of being a leading satellite player.' Article content 'I would like to thank everyone at SES for their outstanding teamwork,' said Sandeep, CFO of SES. 'I am proud of the strides we have made during the past years, and I will continue to cheer SES's progress in the industry.' Article content Incoming CFO Lisa said, 'I look forward to stepping into this new position and working with everyone at SES to jointly deliver an exciting future for the years to come.' Article content Lisa joins SES from Aerojet Rocketdyne, an L3Harris Company, where she helped expand profitability through streamlining operations and prioritising capital investments for long-term growth. As Group CFO for the Comet Group from 2020-2023, she drove EBITDA margin expansion of over 5 percentage points. In her 10-year progressive career (2005-2015) across RTX Corporation (formerly Raytheon Technologies Corporation), she held multiple finance roles and led the financial integration of Applied Signal Technologies, one of Raytheon's largest acquisitions in 2011. Article content Twitter Article content | Article content Facebook Article content | Article content YouTube Article content | Article content LinkedIn Article content | Article content Instagram Article content Article content Article content Visit the Media Gallery > Article content About SES Article content SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous earth orbit (GEO) fleet and medium earth orbit (MEO) constellation of satellites, offering a combination of global coverage and high-performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: Article content Article content Contacts Article content
Globe and Mail
6 hours ago
- Globe and Mail
Winline Technology Debuts 1500V High-Voltage DC Module UXC150030 at Power2Drive Europe 2025, Accelerating Global Green Energy Transition
Munich, Germany--(Newsfile Corp. - June 5, 2025) - Winline Technology globally premiered its 1500V high-voltage isolated unidirectional DC/DC module, UXC150030, at the Power2Drive Europe exhibition in Munich, Germany, showcasing its latest innovations in green energy solutions. Alongside a full portfolio of charging and energy systems, the company attracted significant attention from European and global industry stakeholders through keynote speeches, product demonstrations, and technical exchanges. To view an enhanced version of this graphic, please visit: During the product launch, Dr. Tong Cheng, Vice President of Overseas Marketing at Winline Technology, delivered a keynote speech highlighting the module's technical breakthroughs and application potential. Designed for ultra-high-voltage scenarios such as photovoltaic power generation, energy storage systems, MW-level mining trucks, and rail transit, the UXC150030 features an ultra-wide dual-terminal voltage range of 200-1500Vdc and a peak conversion efficiency of 98.5%. Leveraging third-generation semiconductor technology and proprietary topology design, the module minimizes energy loss while maintaining stable operation across temperatures from -40°C to +75°C, ensuring reliability in extreme climates and industrial environments. "UXC150030 is not only a technological milestone but also a precise response to the demands of the high-voltage DC market. It will provide standardized and highly compatible support for Europe's energy transition," emphasized Dr. Cheng. At the exhibition, Winline Technology demonstrated the innovative value of its product lineup through live displays and scenario-based explanations. The bidirectional DC/DC energy storage module UXC95050B, with a peak efficiency of 98.8% and dual-terminal voltage coverage of 200-950Vdc, serves as a core component for integrated solar-storage-charging systems and data center energy management. The high-power isolated module UXC100040, with an output range of 50-1000Vdc, addresses multi-vehicle fast charging and retired battery reuse needs. The liquid-cooled charging module LCR100040A combines IP50 protection with silent cooling technology to overcome challenges in corrosive and noise-sensitive environments. Meanwhile, the bidirectional AC/DC module UKG1K02-2, supporting a wide DC voltage range of 150-1000Vdc and AC voltage range of 260-530Vac, empowers V2G and smart energy networks. To address Europe's critical energy challenges-grid instability and urgent renewable energy integration-Winline Technology aligns its innovations with market trends. As Europe accelerates the adoption of DC microgrids to reduce AC/DC conversion losses and system costs, the company is committed to advancing hybrid AC/DC grid solutions through modular and scenario-driven designs. Moving forward, Winline Technology will deepen collaborations with European energy enterprises to drive intelligent grid upgrades, fostering a more stable and cost-effective green energy ecosystem across the continent.
